

Patients 18 years or older with a suspected diagnosis or a confirmed family history of hereditary ATTR (hATTR) amyloidosis are invited to take part in the Alnylam Act™ program, a no-charge U.S. genetic testing program brought to you by Alnylam Pharmaceuticals and Invitae Corporation.

Please fill out, print, and sign this checklist and include it when sending in the specimen. Additional information about the ordering process can be found at [www.invitae.com/alnylam-act-ttr](http://www.invitae.com/alnylam-act-ttr).

To submit orders for genetic testing outside of this program, please order through Invitae's online portal or use a standard requisition form, accessible at [www.invitae.com/order-forms](http://www.invitae.com/order-forms).

Patient name	Date of birth (MM/DD/YYYY)
--------------	----------------------------

*Patient must be 18 years or older*

## ALNYLAM ACT (TTR) SYMPTOM CHECKLIST

**Please check all that apply:**

- Family history of hATTR amyloidosis
- Sensory and motor (e.g. neuropathic pain, alternation sensation [sensitivity to pain and temperature], numbness and tingling, muscle weakness, impaired balance, difficulty walking)
- Autonomic dysfunction (nausea and vomiting, changes in GI motility [diarrhea, constipation, gastroparesis, early satiety], orthostatic hypotension [fainting and dizziness upon standing], erectile dysfunction, bladder dysfunction)
- Heart disease (e.g., shortness of breath, edema, palpitations and arrhythmias)
- Carpal tunnel syndrome
- Generalized fatigue
- Unintentional weight loss
- Ocular changes (e.g., blurred vision, blindness)
- Other: \_\_\_\_\_

By signing this form, the medical professional acknowledges that the individual/family member authorized to make decisions for the individual (collectively, the "Patient") has been supplied information regarding and consented to undergo genetic testing, substantially as set forth in Invitae's Informed Consent for Genetic Testing ([www.invitae.com/patient-consent](http://www.invitae.com/patient-consent)) and in connection with the Alnylam Act program, and has been informed that Invitae may notify them of clinical updates related to genetic test results (in consultation with the ordering medical professional as indicated). The medical professional also hereby acknowledges that organization and clinician contact information provided in the order may be shared with third parties, including Alnylam Pharmaceuticals, that may contact you directly in connection with the Alnylam Act program. In addition to the above, I attest that I am the ordering physician, or I am authorized by the ordering physician to order this test, or I am authorized under applicable state law to order this test.

 Medical professional signature	Date
--	------